Clinical Trials
6 trialsNCT03215693 2023-08-16
X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT03574402 2022-12-06
TRUMP
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT05380024 2022-08-18
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05178511 2022-01-05
ERSGATR
Sun Yat-sen University
Phase 2 Unknown
NCT04415320 2020-06-04
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT03608007 2020-01-09
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown